Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDr. Martens Regulatory News (DOCS)

Share Price Information for Dr. Martens (DOCS)

Share Price is delayed by 15 minutes
Get Live Data
70.00    -2.30 (-3.18%)
Bid:
71.00
Ask:
71.30
Spread: 0.30 (0.423%)
Market Cap: £669.96m
DOCS Live PriceLast checked at - London Stock Exchange

Intraday Dr. Martens Share Chart

CFO retirement

14 Apr 2023 07:01

RNS Number : 1908W
Dr. Martens PLC
14 April 2023
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

 

14 April 2023

Dr. Martens plc

("the Company")

 

CFO retirement

 

Dr. Martens Plc today announces that, with agreement of the Board, Jon Mortimore has decided to retire from his role as Chief Financial Officer (CFO) of the Company. Jon will continue in his role until a successor is in place to ensure a smooth transfer of responsibilities.

The Company is commencing an external search for Jon's successor.

Jon joined the company in April 2016. During his seven years at Dr. Martens, Jon has been instrumental in delivering the Company's transition from a family-run company to a listed PLC, overseeing revenue growth from £230m to £1bn, as well as playing an integral role in the Company's initial public offering (IPO) in January 2021.

Paul Mason, Dr. Martens Chair said "On behalf of the Board, I would like to thank Jon for his central role in driving the strong growth and strategic development of Dr. Martens over the last seven years. His knowledge of the business and understanding of the Company's value drivers have played a key part in helping develop the business during this period. We also want to thank him for his careful stewardship of the finance function, in particular during the pandemic period, which is testament to his dedication and exceptional hard work. We wish him well in his retirement."

Jon Mortimore, CFO added "I am proud of the progress that Dr. Martens has achieved during my time as CFO since 2016 and I look forward to seeing further growth and success in the years to come. This is a great company with an incredible brand and passionate people, and I believe it has a very exciting long-term future ahead of it. I will be retiring once my successor is in place but until then, I will continue to support Dr. Martens in my role as CFO."

 

Enquiries

Investors and analysts

Mark Blythman, Interim Director of Investor Relations Mark.Blythman@drmartens.com +44 7570 871207

Beth Callum, Senior Investor Relations Analyst Beth.callum@drmartens.com +44 203 995 2644

 

Press

Maitland +44 207 379 5151

Clinton Manning +44 7711 972662

 

Gill Hammond, Director of Communications +44 7384 214248

 

This announcement contains inside information. The person responsible for arranging the release of this announcement on behalf of the Company is Emily Reichwald, Chief People and Sustainability Officer and Company Secretary.

 

About Dr. Martens

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Produced originally for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens has since transcended its working-class roots while still celebrating its proud heritage and, six decades later, "Docs" or "DM's" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. The Company is a constituent of the FTSE 250 index.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAIJMLTMTABBPJ
Date   Source Headline
31st Jul 20243:43 pmRNSTotal Voting Rights
12th Jul 202412:42 pmRNSDirector/PDMR Shareholding
11th Jul 202411:05 amRNSResult of AGM
11th Jul 20247:00 amRNSAGM Trading Update
1st Jul 202412:44 pmRNSTotal Voting Rights
18th Jun 202412:00 pmRNSBlock listing Interim Review
14th Jun 202412:51 pmRNSDirector/PDMR Shareholding
14th Jun 202412:50 pmRNSDirector/PDMR Shareholding
12th Jun 20244:35 pmRNSHolding(s) in Company
12th Jun 20244:35 pmRNSTechnical change in Permira ownership structure
12th Jun 20244:35 pmRNSHolding(s) in Company
12th Jun 202412:20 pmRNSDirector/PDMR Shareholding
12th Jun 20249:00 amRNSAnnual Financial Report
3rd Jun 20249:00 amRNSDirector/PDMR Shareholding
3rd Jun 20249:00 amRNSCompany Secretary Change
31st May 20247:00 amRNSTotal Voting Rights
30th May 20247:00 amRNSFY24 Results
14th May 20241:24 pmRNSDirector/PDMR Shareholding
10th May 20247:00 amRNSCFO start date - update
1st May 20244:14 pmRNSTotal Voting Rights
16th Apr 20247:00 amRNSCEO succession
16th Apr 20247:00 amRNSFY24 trading and FY25 outlook update
12th Apr 20243:13 pmRNSDirector/PDMR Shareholding
28th Mar 20245:56 pmRNSTotal Voting Rights
12th Mar 20243:50 pmRNSDirector/PDMR Shareholding
1st Mar 202411:19 amRNSTotal Voting Rights
27th Feb 20247:00 amRNSCFO appointment update
14th Feb 20244:10 pmRNSDirector/PDMR Shareholding
5th Feb 20242:13 pmRNSDirector/PDMR Shareholding
1st Feb 202410:40 amRNSTotal Voting Rights
25th Jan 20247:00 amRNSQ3 FY24 Trading Statement
12th Jan 20241:58 pmRNSDirector/PDMR Shareholding
2nd Jan 202410:13 amRNSTotal Voting Rights
15th Dec 20236:20 pmRNSTransaction in Own Shares
14th Dec 20236:15 pmRNSTransaction in Own Shares
13th Dec 20236:02 pmRNSTransaction in Own Shares
12th Dec 20236:24 pmRNSTransaction in Own Shares
12th Dec 20231:42 pmRNSDirector/PDMR Shareholding
11th Dec 20236:04 pmRNSTransaction in Own Shares
8th Dec 20236:16 pmRNSTransaction in Own Shares
7th Dec 20236:23 pmRNSTransaction in Own Shares
6th Dec 20236:08 pmRNSTransaction in Own Shares
5th Dec 20236:20 pmRNSTransaction in Own Shares
4th Dec 20236:29 pmRNSTransaction in Own Shares
1st Dec 20236:20 pmRNSTransaction in Own Shares
1st Dec 20232:08 pmRNSHolding(s) in Company
1st Dec 20238:00 amRNSBlock listing Interim Review
30th Nov 20234:08 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSHalf-year Report
20th Nov 20236:07 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.